From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights

Samuele De Minicis; Chris Day; Gianluca Svegliati-Baroni

From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights

Curr Pharm Des. 2013;19(29):5239-49.

Authors

Samuele De Minicis¹, Chris Day, Gianluca Svegliati-Baroni

Affiliation

¹ Department of Gastroenterology, Universita Politecnica delle Marche, Italy.

PMID: 23394093

Abstract

NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Carcinoma, Hepatocellular / complications*
Carcinoma, Hepatocellular / therapy
Fatty Liver / etiology*
Fatty Liver / therapy
Humans
Liver Neoplasms / complications*
Liver Neoplasms / therapy
Non-alcoholic Fatty Liver Disease